JP2014533239A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014533239A5 JP2014533239A5 JP2014536147A JP2014536147A JP2014533239A5 JP 2014533239 A5 JP2014533239 A5 JP 2014533239A5 JP 2014536147 A JP2014536147 A JP 2014536147A JP 2014536147 A JP2014536147 A JP 2014536147A JP 2014533239 A5 JP2014533239 A5 JP 2014533239A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding antibody
- aho position
- threonine
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000427 antigen Substances 0.000 claims description 49
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 18
- 239000004473 Threonine Substances 0.000 claims description 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 18
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 14
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 10
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 10
- 102000036639 antigens Human genes 0.000 claims description 10
- 108091007433 antigens Proteins 0.000 claims description 10
- 239000004475 Arginine Substances 0.000 claims description 6
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 claims description 6
- 101000588258 Taenia solium Paramyosin Proteins 0.000 claims description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 4
- 235000001014 amino acid Nutrition 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 4
- 239000004474 valine Substances 0.000 claims description 4
- 239000004471 Glycine Substances 0.000 claims description 2
- 101001057612 Homo sapiens Dual specificity protein phosphatase 5 Proteins 0.000 claims description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 2
- 235000004279 alanine Nutrition 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 102000043381 human DUSP5 Human genes 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161549482P | 2011-10-20 | 2011-10-20 | |
| US61/549,482 | 2011-10-20 | ||
| PCT/EP2012/004404 WO2013056851A2 (en) | 2011-10-20 | 2012-10-19 | Stable multiple antigen-binding antibody |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017084447A Division JP2017125066A (ja) | 2011-10-20 | 2017-04-21 | 安定な複数抗原結合抗体 |
| JP2019067016A Division JP2019104759A (ja) | 2011-10-20 | 2019-03-29 | 安定な複数抗原結合抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014533239A JP2014533239A (ja) | 2014-12-11 |
| JP2014533239A5 true JP2014533239A5 (cg-RX-API-DMAC7.html) | 2015-08-06 |
Family
ID=47115743
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014536147A Withdrawn JP2014533239A (ja) | 2011-10-20 | 2012-10-19 | 安定な複数抗原結合抗体 |
| JP2017084447A Pending JP2017125066A (ja) | 2011-10-20 | 2017-04-21 | 安定な複数抗原結合抗体 |
| JP2019067016A Pending JP2019104759A (ja) | 2011-10-20 | 2019-03-29 | 安定な複数抗原結合抗体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017084447A Pending JP2017125066A (ja) | 2011-10-20 | 2017-04-21 | 安定な複数抗原結合抗体 |
| JP2019067016A Pending JP2019104759A (ja) | 2011-10-20 | 2019-03-29 | 安定な複数抗原結合抗体 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20130101586A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2768855B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP2014533239A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20140082700A (cg-RX-API-DMAC7.html) |
| CN (2) | CN109608543A (cg-RX-API-DMAC7.html) |
| AR (1) | AR088403A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012325232B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112014009030A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2850572A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2687245T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2014004521A (cg-RX-API-DMAC7.html) |
| RU (2) | RU2652886C2 (cg-RX-API-DMAC7.html) |
| TW (1) | TWI577696B (cg-RX-API-DMAC7.html) |
| UY (1) | UY34404A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013056851A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| WO2012016227A2 (en) | 2010-07-29 | 2012-02-02 | Xencor, Inc. | Antibodies with modified isoelectric points |
| US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| US12466897B2 (en) | 2011-10-10 | 2025-11-11 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| HRP20191865T1 (hr) | 2013-01-14 | 2020-01-10 | Xencor, Inc. | Novi heterodimerni proteini |
| US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
| US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
| US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
| US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
| US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
| US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
| CA2897987A1 (en) | 2013-01-15 | 2014-07-24 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
| US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
| US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| DK2970486T3 (en) | 2013-03-15 | 2018-08-06 | Xencor Inc | MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS |
| SG11201607983YA (en) | 2014-03-28 | 2016-10-28 | Xencor Inc | Bispecific antibodies that bind to cd38 and cd3 |
| JP6223898B2 (ja) * | 2014-04-24 | 2017-11-01 | 株式会社パイロットコーポレーション | スタンプ用水性インキ組成物及びそれを内蔵したスタンプ |
| TWI806150B (zh) * | 2014-11-07 | 2023-06-21 | 瑞士商諾華公司 | 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物 |
| RS62332B1 (sr) | 2014-11-26 | 2021-10-29 | Xencor Inc | Heterodimerna antitela koja vezuju cd3 i cd20 |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| CN107406512A (zh) | 2014-11-26 | 2017-11-28 | Xencor公司 | 结合cd3和cd38的异二聚体抗体 |
| US10428155B2 (en) | 2014-12-22 | 2019-10-01 | Xencor, Inc. | Trispecific antibodies |
| US10227411B2 (en) | 2015-03-05 | 2019-03-12 | Xencor, Inc. | Modulation of T cells with bispecific antibodies and FC fusions |
| US11623957B2 (en) | 2015-12-07 | 2023-04-11 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and PSMA |
| IL263542B2 (en) | 2016-06-14 | 2024-10-01 | Xencor Inc | Bispecific antibodies inhibit immunological checkpoint |
| CN116063545A (zh) | 2016-06-28 | 2023-05-05 | Xencor股份有限公司 | 结合生长抑素受体2的异源二聚抗体 |
| CN106222129A (zh) * | 2016-07-29 | 2016-12-14 | 广东东阳光药业有限公司 | 一种提高抗体纯度的细胞培养基和培养方法 |
| US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| MA46534A (fr) | 2016-10-14 | 2019-08-21 | Xencor Inc | Protéines de fusion fc hétérodimères il15/il15r |
| WO2019006472A1 (en) | 2017-06-30 | 2019-01-03 | Xencor, Inc. | TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS |
| CN112272563A (zh) | 2017-11-08 | 2021-01-26 | Xencor股份有限公司 | 使用新颖抗pd-1序列的双特异性和单特异性抗体 |
| US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| IL275426B2 (en) | 2017-12-19 | 2025-03-01 | Xencor Inc | Engineered il-2 fc fusion proteins |
| AU2019247415A1 (en) | 2018-04-04 | 2020-10-22 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
| EP3781598A1 (en) | 2018-04-18 | 2021-02-24 | Xencor, Inc. | Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains |
| KR20210010862A (ko) | 2018-04-18 | 2021-01-28 | 젠코어 인코포레이티드 | IL-15/IL-15Rα Fc-융합 단백질 및 PD-1 항원 결합 도메인을 함유하는 PD-1 표적화 이종이량체 융합 단백질 및 이의 용도 |
| JP7612571B2 (ja) | 2018-10-03 | 2025-01-14 | ゼンコア インコーポレイテッド | Ｉｌ－１２ヘテロ二量体ｆｃ－融合タンパク質 |
| JP2022516622A (ja) * | 2019-01-03 | 2022-03-01 | アムジエン・インコーポレーテツド | 安定性及び生産力価を向上させるためのモノクローナル抗体操作 |
| BR112021016955A2 (pt) | 2019-03-01 | 2021-11-23 | Xencor Inc | Composição, composição de ácido nucleico, composição de vetor de expressão, vetor de expressão, célula hospedeira, métodos de produção de um domínio de ligação de membro de família 3 de pirofosfatase/fosfodiesterase de ectonucleotídeo e de tratamento de um câncer, anticorpo anti-enpp3, e, anticorpo heterodimérico |
| JP7692188B2 (ja) * | 2019-11-05 | 2025-06-13 | 国立大学法人 琉球大学 | 耐熱性を付与した抗真菌タンパク質，ならびにこれを有効成分とする薬剤とその使用 |
| US11919956B2 (en) | 2020-05-14 | 2024-03-05 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3 |
| US11919958B2 (en) | 2020-08-19 | 2024-03-05 | Xencor, Inc. | Anti-CD28 compositions |
| KR20230156079A (ko) | 2021-03-09 | 2023-11-13 | 젠코어 인코포레이티드 | Cd3과 cldn6에 결합하는 이종이량체 항체 |
| EP4305065A1 (en) | 2021-03-10 | 2024-01-17 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and gpc3 |
| EP4642232A1 (en) * | 2022-12-30 | 2025-11-05 | Biotalys NV | Self-emulsifiable concentrate |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| BRPI9707379B8 (pt) * | 1996-02-09 | 2015-07-07 | Abbvie Biotechnology Ltd | Composições farmacêuticas compreendendo anticorpo humano recombinante geneticamente engenheirado, e anticorpo humano recombinante geneticamente engenheirado. |
| HUP9900956A2 (hu) | 1998-04-09 | 2002-04-29 | Aventis Pharma Deutschland Gmbh. | Egyláncú, több antigéntkötőhely kialakítására képes molekulák, előállításuk és alkalmazásuk |
| DE19819846B4 (de) | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalente Antikörper-Konstrukte |
| CA2408594A1 (en) * | 2000-05-08 | 2001-11-15 | Medarex, Inc. | Human monoclonal antibodies to dendritic cells |
| JP4166262B2 (ja) * | 2001-12-28 | 2008-10-15 | 中外製薬株式会社 | タンパク質安定化方法 |
| US8853362B2 (en) | 2002-05-22 | 2014-10-07 | Esbatech, An Alcon Biomedical Research Unit Llc | Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same |
| WO2003106497A1 (en) * | 2002-06-14 | 2003-12-24 | Immunomedics, Inc. | Monoclonal antibody pam4 and its use for diagnosis and therapy of pancreatic cancer |
| EP1539947A4 (en) * | 2002-08-15 | 2006-09-06 | Epitomics Inc | HUMANIZED RABBIT ANTIBODIES |
| MY150740A (en) * | 2002-10-24 | 2014-02-28 | Abbvie Biotechnology Ltd | Low dose methods for treating disorders in which tnf? activity is detrimental |
| EP2395026B1 (en) * | 2005-02-08 | 2018-01-24 | The Chemo-Sero-Therapeutic Research Institute | Method for improving antibody |
| US9241994B2 (en) * | 2005-06-10 | 2016-01-26 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical compositions containing sc(Fv)2 |
| CA2646508A1 (en) * | 2006-03-17 | 2007-09-27 | Biogen Idec Ma Inc. | Stabilized polypeptide compositions |
| WO2008004834A1 (en) | 2006-07-06 | 2008-01-10 | Isu Abxis Co., Ltd | Humanized monoclonal antibody highly binding to epidermal growth factor receptor, egf receptor |
| AU2008265984B2 (en) * | 2007-06-21 | 2014-07-17 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| KR101573086B1 (ko) * | 2007-06-25 | 2015-11-30 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | 항체를 변형시키는 방법, 및 기능적 특성이 개선된 변형된 항체 |
| WO2009082624A2 (en) * | 2007-12-10 | 2009-07-02 | Zymogenetics, Inc. | Antagonists of il-17a, il-17f, and il-23 and methods of using the same |
| AU2009264564B2 (en) * | 2008-06-25 | 2014-05-08 | Novartis Ag | Stable and soluble antibodies inhibiting TNFalpha |
| SI2752428T1 (sl) | 2008-06-25 | 2020-03-31 | Novartis Ag | Humaniziranje zajčjih protiteles z uporabo univerzalnega ogrodja protitelesa |
| KR101678925B1 (ko) | 2008-06-30 | 2016-11-24 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | 기능화 폴리펩티드 |
| EP2313502A4 (en) * | 2008-07-14 | 2012-04-04 | Uchicago Argonne Llc | METHODS FOR SYSTEMATICALLY CONTROLLING THE STABILITY OF A PROTEIN |
| CN102164960A (zh) * | 2008-09-26 | 2011-08-24 | 罗氏格黎卡特股份公司 | 双特异性抗-egfr/抗-igf-1r抗体 |
| US8268314B2 (en) * | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| CA2742786A1 (en) * | 2008-11-13 | 2010-05-20 | Femta Pharmaceuticals, Inc. | Humanized anti-il-6 antibodies |
| AR083495A1 (es) * | 2010-10-22 | 2013-02-27 | Esbatech Alcon Biomed Res Unit | Anticuerpos estables y solubles |
-
2012
- 2012-10-19 CN CN201811254222.0A patent/CN109608543A/zh active Pending
- 2012-10-19 US US13/655,743 patent/US20130101586A1/en not_active Abandoned
- 2012-10-19 KR KR1020147009866A patent/KR20140082700A/ko not_active Ceased
- 2012-10-19 TW TW101138704A patent/TWI577696B/zh not_active IP Right Cessation
- 2012-10-19 UY UY0001034404A patent/UY34404A/es not_active Application Discontinuation
- 2012-10-19 CN CN201280051247.5A patent/CN103890005A/zh active Pending
- 2012-10-19 JP JP2014536147A patent/JP2014533239A/ja not_active Withdrawn
- 2012-10-19 WO PCT/EP2012/004404 patent/WO2013056851A2/en not_active Ceased
- 2012-10-19 RU RU2014120154A patent/RU2652886C2/ru not_active IP Right Cessation
- 2012-10-19 ES ES12780659.4T patent/ES2687245T3/es active Active
- 2012-10-19 RU RU2018112861A patent/RU2018112861A/ru not_active Application Discontinuation
- 2012-10-19 MX MX2014004521A patent/MX2014004521A/es unknown
- 2012-10-19 BR BR112014009030A patent/BR112014009030A2/pt not_active IP Right Cessation
- 2012-10-19 EP EP12780659.4A patent/EP2768855B1/en active Active
- 2012-10-19 EP EP18177236.9A patent/EP3431495A1/en not_active Withdrawn
- 2012-10-19 CA CA2850572A patent/CA2850572A1/en not_active Abandoned
- 2012-10-19 AR ARP120103914A patent/AR088403A1/es unknown
- 2012-10-19 AU AU2012325232A patent/AU2012325232B2/en not_active Ceased
-
2017
- 2017-04-21 JP JP2017084447A patent/JP2017125066A/ja active Pending
-
2019
- 2019-02-27 US US16/286,816 patent/US20200048336A1/en not_active Abandoned
- 2019-03-29 JP JP2019067016A patent/JP2019104759A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014533239A5 (cg-RX-API-DMAC7.html) | ||
| RU2018112861A (ru) | Стабильные антитела, связывающиеся с несколькими антигенами | |
| JP2010539921A5 (cg-RX-API-DMAC7.html) | ||
| WO2016207304A8 (en) | Monoclonal anti-il-1racp antibodies | |
| JP2010536384A5 (cg-RX-API-DMAC7.html) | ||
| HRP20230844T1 (hr) | Anti-cd3 antitijela, bispecifične molekule koje vežu antigen koji veže cd3 i cd20, i njihove upotrebe | |
| RU2018102606A (ru) | Молекулы, связывающиеся с psl pseudomonas, и пути их применения | |
| EA201990570A1 (ru) | Моноклональное антитело против pd1, его фармацевтическая композиция и их применение | |
| JP2017500018A5 (cg-RX-API-DMAC7.html) | ||
| JP2016507523A5 (cg-RX-API-DMAC7.html) | ||
| JP2017176174A5 (cg-RX-API-DMAC7.html) | ||
| CY1120414T1 (el) | Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους | |
| JP2009225799A5 (cg-RX-API-DMAC7.html) | ||
| JP2018537415A5 (cg-RX-API-DMAC7.html) | ||
| JP2017504578A5 (cg-RX-API-DMAC7.html) | ||
| JP2015504421A5 (cg-RX-API-DMAC7.html) | ||
| HRP20200390T1 (hr) | Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma) | |
| HRP20201517T1 (hr) | Anti-cd3 protutijela, anti-cd123 protutijela i bispecifična protutijela koja se specifično vežu na cd3 i/ili cd123 | |
| ES2776179T3 (es) | Anticuerpos dirigidos contra determinantes de la superficie de S. aureus | |
| EA201190132A1 (ru) | Гуманизированные антитела, связывающиеся с cd19, и их применение | |
| JP2018505674A5 (cg-RX-API-DMAC7.html) | ||
| JP2012525829A5 (cg-RX-API-DMAC7.html) | ||
| TR201817932T4 (en) | ANTIBODIES THAT BIND STAPHYLOCOCCUS AUREUS ALPHA TOXIN SPECIFICALLY AND METHODS OF USE | |
| JP2016536322A5 (cg-RX-API-DMAC7.html) | ||
| RU2016100892A (ru) | Антитела против tweakr и их применение |